Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Esperion licenses Pharmacia & Upjohn's anti-atherogenic

Executive Summary

Private atherosclerosis therapy start-up Esperion Therapeutics has licensed worldwide rights from Pharmacia & Upjohn to recombinant human ApoA-I Milano, a variant of apolipoprotien A-I, which shows anti-atherogenic activity in preclinical studies.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Co-Promotion
    • Includes Contract
    • Reverse Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register